At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 235 enrolled
Drug / intervention
peginterferon alfa-2a +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-label Study of the Effects of 24 vs 48 Weeks of Combination Therapy With PEGASYS (Peginterferon Alfa-2a 40KD) Plus COPEGUS (Ribavirin) on Sustained Virological Response in Patients With Chronic Hepatitis C, Genotype 2 or 3 Who do Not Achieve a Rapid Viral Response
In Brief
A Phase 3 clinical trial evaluating peginterferon alfa-2a and Ribavirin for Hepatitis C, Chronic. Completed, enrolled 235 participants across 101 sites in 10 countries.
Detailed Summary
This study will evaluate the efficacy and safety of peginterferon alfa-2a 40KD + ribavirin combination therapy given for 24 weeks versus 48 weeks in patients with chronic hepatitis C, genotype 2/3.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
CountriesAustralia, Austria, Belgium, Brazil, Canada, Germany, Mexico, Puerto Rico, Switzerland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2008
Enrollment StartJun 2008
Primary CompletionMay 2012
TodayJul 2026
First PostedFeb 26, 2008
Enrollment StartJun 1, 2008
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 18.3 years ago
Interventions
peginterferon alfa-2adrug
Ribavirindrug